Understanding how too much EWS/FLI1 protein affects Ewing sarcoma cells
Official title: Mechanisms of Toxicity Induced by EWS/FLI1 Overdose in Ewing Sarcoma
Funded at Dana-Farber Cancer Inst · NIH-11085216 · Data updated 2026-11-12
This study is looking at how high levels of a specific protein affect Ewing sarcoma, a type of bone cancer that mostly affects kids, to find out how we can help make cancer cells die off and discover new ways to treat this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | June 7, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $713,593 |
| NIH project number | 5R01CA283395-03 |
| Project ID | NIH-11085216 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children diagnosed with Ewing sarcoma, particularly those aged 0-11 years.
✕Less likely to help
Patients with other types of cancers or those who do not have Ewing sarcoma may not benefit from this research.
What this research studies
This research investigates the effects of excessive levels of the EWS/FLI1 fusion protein in Ewing sarcoma, a common bone cancer in children. The study aims to uncover the mechanisms that lead to cell death when these protein levels are too high, as well as how they are regulated within a safe range. By using advanced techniques like CRISPR and shRNA, researchers will explore how manipulating these protein levels can impact cancer cell survival. The findings could provide insights into new treatment strategies for Ewing sarcoma and potentially other related cancers.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that improve outcomes for children with Ewing sarcoma.
How similar studies have gone: While the specific approach of studying EWS/FLI1 overdose is relatively novel, similar research on EWS fusion proteins has shown promising results in understanding cancer biology.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Stegmaier, Kimberly — Dana-Farber Cancer Inst
- Study coordinator: Stegmaier, Kimberly
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.